{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:58:48Z","timestamp":1790787528540,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["Unrestricted educational grant"],"award-info":[{"award-number":["Unrestricted educational grant"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-1172-8","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T11:02:36Z","timestamp":1565348556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry"],"prefix":"10.1186","volume":"14","author":[{"name":"the RIETE Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-804X","authenticated-orcid":false,"given":"Antoni","family":"Riera-Mestre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Mora-Luj\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Trujillo-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Del Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Pedrajas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"L\u00f3pez-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitor","family":"Ballaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Cerd\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Monreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,9]]},"reference":[{"key":"1172_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13023-018-0850-2","volume":"13","author":"CL Shovlin","year":"2018","unstructured":"Shovlin CL, Buscarini E, Kjeldsen AD, Mager HJ, Sabba C, Droege F, et al. European reference network for rare vascular diseases (VASCERN) outcome measures for hereditary Haemorrhagic telangiectasia. Orphanet J Rare Dis. 2018;13:136.","journal-title":"Orphanet J Rare Dis"},{"key":"1172_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2015.00001","volume":"6","author":"J McDonald","year":"2015","unstructured":"McDonald J, Wooderchak-Donahue W, VanSant Webb C, Whitehead K, Stevenson DA, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015;6:1.","journal-title":"Front Genet"},{"key":"1172_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jmg.2009.069013","volume":"48","author":"ME Faughnan","year":"2011","unstructured":"Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, et al. HHT Foundation International - guidelines working group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48:73\u201387.","journal-title":"J Med Genet"},{"key":"1172_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.medcli.2018.09.015","volume":"152","author":"A Riera-Mestre","year":"2019","unstructured":"Riera-Mestre A, Ribas J, Castellote J. Medical management of haemorrhagic hereditary telangiectasia in adult patients. Med Clin (Barc). 2019;152:274\u201380.","journal-title":"Med Clin (Barc)"},{"key":"1172_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jhep.2006.12.008","volume":"46","author":"G Garcia-Tsao","year":"2007","unstructured":"Garcia-Tsao G. Liver involvement in hereditary hemorrhagic telangiectasia. J Hepatol. 2007;46:499\u2013507.","journal-title":"J Hepatol"},{"key":"1172_CR6","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1183\/13993003.01588-2015","volume":"47","author":"VM Voselaars","year":"2016","unstructured":"Voselaars VM, Velthius S, Snijder RJ, Westermann CJ, Vos JA, Mager JJ, et al. Follow-up of pulmonary right-to-left shunt in hereditary haemorrhagic telangiectasia. Eur Respir J. 2016;47:1750\u20137.","journal-title":"Eur Respir J"},{"key":"1172_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-weber syndrome). Am J Med Genet. 2000;91:66.","journal-title":"Am J Med Genet"},{"key":"1172_CR8","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1161\/ATVBAHA.118.310760","volume":"38","author":"E Alsina-Sanch\u00eds","year":"2018","unstructured":"Alsina-Sanch\u00eds E, Garc\u00eda-Ib\u00e1\u00f1ez Y, Figueiredo AM, Riera-Domingo C, Figueras A, Matias-Guiu X, et al. ALK1 loss results in vascular hyperplasia in mice and humans through PI3K activation. Arterioscler Thromb Vasc Biol. 2018;38:1216\u201329.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1172_CR9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.rce.2018.07.002","volume":"218","author":"A Riera-Mestre","year":"2018","unstructured":"Riera-Mestre A, Mora Luj\u00e1n JM, Sanchez Mart\u00ednez R, Torralba Cabeza MA. Patier de la Pe\u00f1a JL, Juyol Rodrigo MC, et al, on behalf of the researchers of the RiHHTa registry. Computerized registry of patients with hemorrhagic hereditary telangiectasia (RiHHTa registry) in Spain: objectives, methods, and preliminary results. Rev Clin Esp. 2018;218:468\u201376.","journal-title":"Rev Clin Esp"},{"key":"1172_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1160\/TH07-01-0064","volume":"98","author":"CL Shovlin","year":"2007","unstructured":"Shovlin CL, Sulaiman NL, Govani FS, Jackson JE, Begbie ME. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost. 2007;98:1031\u20139.","journal-title":"Thromb Haemost"},{"key":"1172_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/thoraxjnl-2011-201076","volume":"67","author":"JA Livesey","year":"2012","unstructured":"Livesey JA, Manning RA, Meek JH, Jackson JE, Kulinskaya E, Laffan MA, et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli\/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax. 2012;67:328\u201333.","journal-title":"Thorax"},{"key":"1172_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMc1213554","volume":"368","author":"HL Devlin","year":"2013","unstructured":"Devlin HL, Hosman AE, Shovlin CL. Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. N Engl J Med. 2013;368:876\u20138.","journal-title":"N Engl J Med"},{"key":"1172_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.thromres.2018.07.004","volume":"169","author":"S Chaturvedi","year":"2018","unstructured":"Chaturvedi S, Kohli R, Schaefer N, Clancy M, Kasthuri RS. Characteristics and outcomes of venous thromboembolism in patients with hereditary hemorrhagic telangiectasia. Thromb Res. 2018;169:41\u20133.","journal-title":"Thromb Res"},{"key":"1172_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1160\/TH08-06-0390","volume":"100","author":"JA Nieto","year":"2008","unstructured":"Nieto JA, Camara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, et al. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:789\u201396.","journal-title":"Thromb Haemost"},{"key":"1172_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/archinternmed.2010.199","volume":"170","author":"D Jim\u00e9nez","year":"2010","unstructured":"Jim\u00e9nez D, Aujesky D, Moores L, G\u00f3mez V, Lobo JL, Uresandi F, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170:1383\u20139.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1172_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1538-7836.2012.04698.x","volume":"10","author":"A. RIERA-MESTRE","year":"2012","unstructured":"Riera-Mestre A, Jim\u00e9nez D, Muriel A, Lobo JL, Moores L, Yusen RD, et al; RIETE investigators. Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism. J Thromb Haemost. 2012;10:751\u20139.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"1172_CR17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1055\/s-0037-1621716","volume":"44","author":"B Bikdeli","year":"2018","unstructured":"Bikdeli B, Sharif-Kashani B, Bikdeli B, Valle R, Falga C, Riera-Mestre A, et al. RIETE investigators. Impact of Thrombus sidedness on presentation and outcomes of patients with proximal lower extremity deep vein thrombosis. Semin Thromb Hemost. 2018;44:341\u20137.","journal-title":"Semin Thromb Hemost"},{"key":"1172_CR18","doi-asserted-by":"crossref","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP;STROBE initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138.","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"1172_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/lary.20818","volume":"120","author":"JB Hoag","year":"2010","unstructured":"Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagia telangiectasia. Laryngoscope. 2010;120:838\u201343.","journal-title":"Laryngoscope"},{"key":"1172_CR20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4193\/Rhino11.211","volume":"50","author":"D Morais","year":"2012","unstructured":"Morais D, Mill\u00e1s T, Zarrabeitia R, Botella LM, Almaraz A. Local sclerotherapy with polydocanol (Aethoxysklerol\u00ae) for the treatment of epistaxis in Rendu-Osler-weber or hereditary hemorrhagic telangiectasia (HHT): 15 years of experience. Rhinology. 2012;50:80\u20136.","journal-title":"Rhinology"},{"key":"1172_CR21","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/jth.12654","volume":"12","author":"S Gaillard","year":"2014","unstructured":"Gaillard S, Dupuis-Girod S, Boutitie F, Rivi\u00e8re S, Morini\u00e8re S, Hatron PY, et al. ATERO study group. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12:1494\u2013502.","journal-title":"J Thromb Haemost"},{"key":"1172_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4193\/Rhino09.201","volume":"49","author":"E Yaniv","year":"2011","unstructured":"Yaniv E, Preis M, Shevro J, Nageris B, Hadar T. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia \u2013 a long-term clinical trial. Rhinology. 2011;49:214\u20136.","journal-title":"Rhinology"},{"key":"1172_CR23","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","volume":"2","author":"R Invernizzi","year":"2015","unstructured":"Invernizzi R, Quaglia F, Klersy C, Pagella F, Ornati F, Chu F, et al. Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-Centre, phase 2 study. Lancet Haematol. 2015;2:e465\u201373.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1172_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-018-0982-4","volume":"14","author":"E Buscarini","year":"2019","unstructured":"Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F, et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2019;14(1):28.","journal-title":"Orphanet J Rare Dis."},{"issue":"4","key":"1172_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.12998\/wjcc.v3.i4.330","volume":"3","author":"Christopher Dittus","year":"2015","unstructured":"Dittus C, Streiff M, Ansell J. Bleeding and clotting in hereditary hemorrhagic telangiectasia. World J Clin Cases. 2015;3:330\u20137.","journal-title":"World Journal of Clinical Cases"},{"key":"1172_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","volume":"157","author":"PV Jenkins","year":"2012","unstructured":"Jenkins PV, Rawley O, Smith OP, O\u2019Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol. 2012;157:653\u201363.","journal-title":"Br J Haematol"},{"key":"1172_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088812","volume":"9","author":"CL Shovlin","year":"2014","unstructured":"Shovlin CL, Chamali B, Santhirapala V, Livesey JA, Angus G, Manning R, et al. Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets. PLoS One. 2014;9:e88812.","journal-title":"PLoS One"},{"key":"1172_CR28","first-page":"CD003747","volume":"5","author":"R Alikhan","year":"2014","unstructured":"Alikhan R, Bedenis R, Cohen AT. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev. 2014;5:CD003747.","journal-title":"Cochrane Database Syst Rev"},{"key":"1172_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315\u201352.","journal-title":"Chest"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1172-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1172-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1172-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T23:15:37Z","timestamp":1596842137000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1172-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1172-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,9]]},"assertion":[{"value":"23 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the local Ethical Committees of the concerned hospitals and was conducted in accordance with the principles of the Helsinki Declaration. All patients (or their relatives) provided written or oral consent for participation in the registry, according to local Ethical Committees requirements.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not contain any individual person\u2019s data in any form. Each patient was identified by a unique alphanumeric identification code and all data were made anonymous and analysed as aggregates.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}